Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity

作者
Nasser Mikhail
出处
期刊:Gastroenterology pancreatology and hepatobilary disorders 卷期号:5 (5): 01-04
标识
DOI:10.31579/2641-5194/044
摘要

Background: Tirzepatide is a dual receptor agonist of the 2 incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) which is currently under development. Objective: To clarify the potential role of tirzepatide for treatment of type 2 diabetes and obesity. Methods: Pubmed search until August 5th, 2021. Search terms were GLP-1, GIP, incretins, tirzepatide, efficacy, safety. Clinical trials and pertinent reviews were included. Results: In one phase 3 clinical trial, mean reduction of glycated hemoglobin (HbA1c) with tirzepatide (5-15 mg/week) was -1.87 to -2.07% versus + 0.04% with placebo after 40 weeks. In another phase 3 randomized trial, tirzepatide decreased HbA1c levels by -2.01% to -2.3% versus -1.86% with semaglutide (1.0 mg/week) (P<0.0001). In the previous 2 studies, tirzepatide use was associated with dose-related mean weight loss at 40 weeks of -7.0 kg o -9.5 kg vs -0.7 kg with placebo (P<0.0001) and -7.6 kg to -11.2 kg vs -5.7 kg with semaglutide ((P<0.001). Tirzepatide had generally favorable effects on lipid profile, particularly on lowering serum triglyceride levels: -19% to -24.8% mean reduction compared with -11.5% with semaglutide. Gastrointestinal (GI) adverse effects were the commonest reported symptoms associated with tirzepatide use and occurred more frequently than with placebo and semaglutide. Hypoglycemia was reported more coomonly with high-dose terzipatide (1.7%) compared with semaglutide (0.4%). Drug discontinuation rates due to adverse effects were 6-8.5 % with tirzepatide vs 4.1% with semaglutide. Conclusions: Available data from 2 short-term randomized trials suggest that tirzepatide may be more effective than placebo and the GLP-1 agonist semaglutide in reducing HbA1c levels and body weight. Pattern of safety profile of tirzepatide is similar to that of GLP-1 agonists, but frequency of GI adverse effects and hypoglycemia is more common with tirzepatide.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天开心完成签到,获得积分10
刚刚
绵羊小姐完成签到 ,获得积分0
刚刚
桑雨关注了科研通微信公众号
1秒前
天真小土豆完成签到 ,获得积分10
1秒前
科研通AI2S的应助被自信的苑博采纳,获得10
2秒前
曈曦完成签到 ,获得积分10
3秒前
高高的外套完成签到,获得积分10
4秒前
健忘的麦片完成签到 ,获得积分10
4秒前
科研通AI6.3的应助被wq采纳,获得10
6秒前
尊嘟假嘟发布了新的文献求助10
7秒前
123完成签到,获得积分10
7秒前
酷波er的应助被多情的天佑采纳,获得10
7秒前
null的应助被hnlgdx采纳,获得10
8秒前
尊嘟假嘟发布了新的文献求助10
8秒前
9秒前
眼科女医生小魏完成签到 ,获得积分10
9秒前
Son4904完成签到,获得积分10
10秒前
初一发布了新的文献求助10
10秒前
所所的应助被WGZ1980049314采纳,获得10
10秒前
小彭陪小崔读个研完成签到 ,获得积分10
11秒前
黄毛虎发布了新的文献求助10
11秒前
憨包完成签到 ,获得积分10
12秒前
lx完成签到,获得积分10
12秒前
CodeCraft的应助被学术超女采纳,获得10
12秒前
快乐曼荷完成签到,获得积分10
13秒前
13秒前
11完成签到,获得积分10
14秒前
w7完成签到 ,获得积分10
15秒前
15秒前
简单静丹完成签到,获得积分10
16秒前
无极微光的应助被薇子采纳,获得20
16秒前
尊嘟假嘟发布了新的文献求助10
16秒前
满意的醉蝶完成签到,获得积分10
17秒前
Alin完成签到,获得积分10
17秒前
18秒前
马世杰发布了新的文献求助20
18秒前
隐形听白完成签到,获得积分10
18秒前
尊嘟假嘟发布了新的文献求助10
18秒前
18秒前
尊嘟假嘟发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186819
求助须知:如何正确求助?哪些是违规求助? 9575195
关于积分的说明 21839872
捐赠科研通 7784526
什么是DOI,文献DOI怎么找? 3434849
关于科研通互助平台的介绍 2559266
邀请新用户注册赠送积分活动 2481716